XML 37 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Shareholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
April 2027 Notes
October 2023 Notes
At-the-market offering program
Public offering
Ordinary shares
Ordinary shares
April 2027 Notes
Ordinary shares
October 2023 Notes
Ordinary shares
At-the-market offering program
Ordinary shares
Public offering
Preferred shares
Preferred shares
Public offering
Additional paid-in capital
Additional paid-in capital
April 2027 Notes
Additional paid-in capital
October 2023 Notes
Additional paid-in capital
At-the-market offering program
Additional paid-in capital
Public offering
Accumulated deficit
Accumulated other comprehensive loss
Beginning balance (in shares) at Dec. 31, 2021           58,620         488                
Beginning balance at Dec. 31, 2021 $ 78,244         $ 586         $ 5   $ 549,349         $ (447,756) $ (23,940)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                      
Net loss (137,464)                                 (137,464)  
Net other comprehensive (loss) income (2,401)                                   (2,401)
Change in fair value of October 2023 Notes conversion feature 5,508                       5,508            
Issuance of common stock, net of issuance costs (in shares)                 3,588                    
Issuance of common stock, net of issuance costs 25,318               $ 36       25,282            
Amortization of deferred issuance costs (45)                       (45)            
Exercise of stock options (in shares)           451                          
Exercise of stock options 2,460         $ 4             2,456            
Vesting of restricted shares (in shares)           144                          
Vesting of restricted shares 0         $ 1             (1)            
Employee share purchase plan share issuance (in shares)           75                          
Employee share purchase plan share issuance 222         $ 1             221            
Share-based compensation expense 7,013                       7,013            
Ending balance (in shares) at Dec. 31, 2022           62,878         488                
Ending balance at Dec. 31, 2022 (21,145)         $ 628         $ 5   589,783         (585,220) (26,341)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                      
Net loss (160,276)                                 (160,276)  
Net other comprehensive (loss) income 3,174                                   3,174
Issuance of common stock, net of issuance costs (in shares)                 1,564 12,205   4,706              
Issuance of common stock, net of issuance costs       $ 11,913 $ 134,151       $ 16 $ 122   $ 47       $ 11,897 $ 133,982    
Amortization of deferred issuance costs (16)                       (16)            
Exchange/Settlement of Notes (in shares)             12,347 408                      
Exchange/Settlement of Notes   $ 101,812 $ 22       $ 123 $ 4           $ 101,689 $ 18        
Exercise of stock options (in shares)           343                          
Exercise of stock options 2,062         $ 4             2,058            
Vesting of restricted shares (in shares)           33                          
Employee share purchase plan share issuance (in shares)           47                          
Employee share purchase plan share issuance 231         $ 1             230            
Share-based compensation expense 15,811                       15,811            
Ending balance (in shares) at Dec. 31, 2023           89,825         5,194                
Ending balance at Dec. 31, 2023 87,739         $ 898         $ 52   855,452         (745,496) (23,167)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                      
Net loss (48,832)                                 (48,832)  
Net other comprehensive (loss) income (1,413)                                   (1,413)
Issuance of common stock, net of issuance costs (in shares)                 640                    
Issuance of common stock, net of issuance costs 9,250               $ 6             $ 9,244      
Amortization of deferred issuance costs (3)                       (3)            
Exchange/Settlement of Notes (in shares)           5,194         (5,194)                
Exchange/Settlement of Notes $ 0         $ 52         $ (52)                
Exercise of stock options (in shares) 734         735                          
Exercise of stock options $ 5,359         $ 8             5,351            
Vesting of restricted shares (in shares)           11                          
Employee share purchase plan share issuance (in shares)           113                          
Employee share purchase plan share issuance 1,361         $ 1             1,360            
Share-based compensation expense 20,387                       20,387            
Ending balance (in shares) at Dec. 31, 2024           96,518         0                
Ending balance at Dec. 31, 2024 $ 73,848         $ 965         $ 0   $ 891,791         $ (794,328) $ (24,580)